RATIONALE: Phosphatidylcholine (PtdCho) in brain cell membranes decreases with age. Evidence from both animal and in vitro studies indicates that CDP-choline (citicoline) administration may increase phosphatidylcholine (PtdCho) synthesis and might reverse PtdCho loss. OBJECTIVES: We investigated whether oral citicoline can increase PtdCho synthesis in the brains of older subjects by measuring levels of phosphorus-containing metabolites using proton-decoupled phosphorus magnetic resonance spectroscopy ((31)P-MRS) before and after citicoline treatment. METHODS: All subjects took 500 mg citicoline once orally each day for 6 weeks, then took either citicoline or placebo once orally per day for a second 6-week period. Subjects underwent a (31)P-MRS scan at baseline and following 6 and 12 weeks of treatment. RESULTS: Treatment with citicoline for 6 weeks was associated with a 7.3% increase from baseline levels in brain phosphodiesters ( P=0.008), including an 11.6% increase in glycerophosphoethanolamine ( P=0.002) and a 5.1% increase in glycerophosphocholine ( P=0.137). Subjects who continued to take citicoline for the second 6-week period did not show significant additional increases in the levels of these metabolites. No changes were seen in other phosphorus-containing metabolites. There was a correlation between improvement on the California Verbal Learning Test and increase in phosphodiesters. CONCLUSIONS: The increases in phosphodiesters seen in this study indicate that phospholipid synthesis and turnover were stimulated by 6 weeks of oral citicoline. These results in humans support previous in vitro and animal studies and suggest that the administration of oral citicoline may be of use in reversing age-related changes in the brain.
RCT Entities:
RATIONALE: Phosphatidylcholine (PtdCho) in brain cell membranes decreases with age. Evidence from both animal and in vitro studies indicates that CDP-choline (citicoline) administration may increase phosphatidylcholine (PtdCho) synthesis and might reverse PtdCho loss. OBJECTIVES: We investigated whether oral citicoline can increase PtdCho synthesis in the brains of older subjects by measuring levels of phosphorus-containing metabolites using proton-decoupled phosphorus magnetic resonance spectroscopy ((31)P-MRS) before and after citicoline treatment. METHODS: All subjects took 500 mg citicoline once orally each day for 6 weeks, then took either citicoline or placebo once orally per day for a second 6-week period. Subjects underwent a (31)P-MRS scan at baseline and following 6 and 12 weeks of treatment. RESULTS: Treatment with citicoline for 6 weeks was associated with a 7.3% increase from baseline levels in brain phosphodiesters ( P=0.008), including an 11.6% increase in glycerophosphoethanolamine ( P=0.002) and a 5.1% increase in glycerophosphocholine ( P=0.137). Subjects who continued to take citicoline for the second 6-week period did not show significant additional increases in the levels of these metabolites. No changes were seen in other phosphorus-containing metabolites. There was a correlation between improvement on the California Verbal Learning Test and increase in phosphodiesters. CONCLUSIONS: The increases in phosphodiesters seen in this study indicate that phospholipid synthesis and turnover were stimulated by 6 weeks of oral citicoline. These results in humans support previous in vitro and animal studies and suggest that the administration of oral citicoline may be of use in reversing age-related changes in the brain.
Authors: Nivedita Agarwal; Young-Hoon Sung; J Eric Jensen; Grace daCunha; David Harper; David Olson; Perry F Renshaw Journal: Bipolar Disord Date: 2010-12 Impact factor: 6.744
Authors: Stephanie C Licata; David M Penetar; Caitlin Ravichandran; John Rodolico; Christopher Palmer; Jeff Berko; Thomas Geaghan; Alison Looby; Erica Peters; Elizabeth Ryan; Perry F Renshaw; Scott E Lukas Journal: J Addict Med Date: 2011-03 Impact factor: 3.702
Authors: David G Harper; David T Plante; J Eric Jensen; Caitlin Ravichandran; Orfeu M Buxton; Kathleen L Benson; Shawn P O'Connor; Perry F Renshaw; John W Winkelman Journal: Sleep Date: 2013-04-01 Impact factor: 5.849
Authors: David G Harper; J Eric Jensen; Caitlin Ravichandran; Yusuf Sivrioglu; Marisa Silveri; Dan V Iosifescu; Perry F Renshaw; Brent P Forester Journal: Am J Geriatr Psychiatry Date: 2013-01-11 Impact factor: 4.105
Authors: Sujung J Yoon; In Kyoon Lyoo; Hengjun J Kim; Tae-Suk Kim; Young Hoon Sung; Namkug Kim; Scott E Lukas; Perry F Renshaw Journal: Neuropsychopharmacology Date: 2009-12-30 Impact factor: 7.853
Authors: Ross Zafonte; William T Friedewald; Shing M Lee; Bruce Levin; Ramon Diaz-Arrastia; Beth Ansel; Howard Eisenberg; Shelly D Timmons; Nancy Temkin; Thomas Novack; Joseph Ricker; Randall Merchant; Jack Jallo Journal: J Neurotrauma Date: 2009-12 Impact factor: 5.269